Search the Newsreel

PSNL|Personalis Inc|Price:11.860|Chg%:-0.120

Personalis Inc (PSNL) has a relatively healthy financial standing and high growth potential, with its valuation considered fairly valued in the biotechnology industry. Multiple analysts have rated it as a Buy, projecting an upward trend in the medium term despite recent weak market performance. …

Materialise NV (MTLS) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Materialise NV (MTLS), ranking it 281 out of 485 in the Software & IT Services industry with a score of 3.80. Key metrics include a beta of 1.32, indicating higher volatility than the S&P 500, a 240-day …

Chemfab Alkalis Limited Reports Earnings Results for the First Quarter Ended June 30, 2026

Medalist Diversified (Nasdaq: MDRR) closes $5.8M Kansas property deal

MTLS|Materialise NV|Price:6.450|Chg%:+0.010

Materialise NV (MTLS) has a high growth potential and healthy fundamentals, with its valuation assessed as fairly valued within the Software & IT Services industry. Analysts rate the stock as "Buy" with a target price of $8.70, suggesting an upward trend in the medium …

Chrysalis Investments Limited (CHRY.L) Stock Analysis: Potential Upside of 78.71% Sparks Investor Interest

American Exceptionalism Acquisition Corp. $AEXA Shares Sold by Polar Asset Management Partners Inc.

Polar Asset Management Partners Inc. significantly reduced its stake in American Exceptionalism Acquisition Corp. (AEXA) by 67.5% in the first quarter, selling 270,076 shares and retaining 129,924 shares valued at approximately $1.41 million. The stock opened at $11.53, near its 50-day moving average, with …

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Luxfer Holdings PLC (NYSE – LXFR), Finward Bancorp (Nasdaq – FNWD), Personalis, Inc. (Nasdaq – PSNL), Distribution Solutions Group, Inc. (Nasdaq – DSGR)

Brodsky & Smith is investigating several companies—Luxfer Holdings PLC (NYSE – LXFR), Finward Bancorp (Nasdaq – FNWD), Personalis, Inc. (Nasdaq – PSNL), and Distribution Solutions Group, Inc. (Nasdaq – DSGR)—regarding potential breaches of fiduciary duties by their boards of directors. These investigations concern whether …

Palisade Bio Draws Bullish Call, Lead IBD Drug Advances Toward Phase 2

Oppenheimer initiated coverage on Palisade Bio Inc. with a Buy rating and a $8 price forecast, highlighting the company's lead drug candidate, PALI-2108, for inflammatory bowel disease (IBD). This oral PDE4 inhibitor prodrug, designed for targeted delivery to the ileum and colon, is advancing …

Talisker Resources Ltd. (TSX: TSK) Gains Momentum as Gold Exploration Progress and Bralorne Project Potential Boost Investor Confidence

Australis Oil & Gas (ASX:ATS) Rises 5% and Extends a 133% Annual Gain

Personalis Inc (PSNL) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Personalis Inc (PSNL), noting its current valuation score of 6.10, which ranks 357 out of 386 in the Biotechnology & Medical Research industry. It highlights the company's current P/E ratio of -11.76, while also indicating that relevant …

Palisade Bio Inc (PALI) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis for Palisade Bio Inc (PALI), stating its current valuation score is 9.13, ranking 54th in the Biotechnology & Medical Research industry. The company's P/E ratio stands at 16.64, which is 13.78% below its recent high and 155.82% above …

Palisade Bio Inc (PALI) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Palisade Bio Inc (PALI)'s dividend and stock split history. It notes that the company has distributed no dividends in the past five years and details several merger-related stock splits that have occurred between 2021 and 2024. The stock …

Palisade Bio Inc (PALI) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Palisade Bio Inc (PALI), noting its current score of 2.82, ranking it 183 out of 386 in the Biotechnology & Medical Research industry. It highlights the company's beta of 1.53, indicating higher volatility compared to the S&P …

Palisade Bio Inc (PALI) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

The article discusses the revenue breakdown for Palisade Bio Inc (PALI), noting that relevant data regarding business segments, regional revenue, and profit contribution have not yet been disclosed by the company. It provides current stock information, including its market cap and P/E ratio, but …

Materialise (Nasdaq: MTLS) pauses EUR 30 million buyback, targets August restart

Materialise (Nasdaq: MTLS) has temporarily suspended its EUR 30 million share buyback program after repurchasing 1,206,380 shares totaling EUR 6,013,083 since January 26, 2026. The suspension, effective July 25, 2026, is due to the inability to renew authorization during a closed period. The company …

Why Talisker Resources Ltd stock is rising today

Tempus AI to Acquire Personalis in $1.5 Billion Deal, Deepening Its Foothold in Cancer Monitoring

Tempus AI (NASDAQ: TEM) has announced its acquisition of Personalis (NASDAQ: PSNL), a molecular residual disease (MRD) specialist, for approximately $1.5 billion. This primarily all-stock deal aims to integrate Personalis's liquid biopsy technology into Tempus's AI-driven precision medicine platform, enhancing its offerings from diagnosis …

Materialise NV (MTLS) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article from TradingKey provides a dividend and stock split history for Materialise NV (MTLS). It notes that a total of 0.00 USD has been distributed in dividends over the past five years, indicating no recent dividend payouts. The page shows current stock information …

Borealis Foods Inc (BRLS) Institutional Confidence

Palisade Bio Inc (PALI) Stock Score & Comprehensive Stock Analysis - Tradingkey

This article provides a comprehensive stock analysis of Palisade Bio Inc (PALI) by TradingKey, assigning it a solid score reflecting healthy fundamentals and high growth potential. The company's valuation is deemed fairly valued within the Biotechnology & Medical Research industry, with high institutional ownership …

PALI|Palisade Bio Inc|Price:2.110|Chg%:-0.040

Palisade Bio Inc (PALI) currently trades at $1.950, reflecting a 3.47% daily decrease. Despite recent stock performance, the company exhibits strong fundamentals, including high growth potential and a "Buy" rating from analysts with a target price of $10.40. Palisade Bio is a clinical-stage biopharmaceutical …

ALIS|Calisa Acquisition Ord Shs|Price:10.150|Chg%:-0.040

This article provides a detailed financial overview of Calisa Acquisition Ord Shs (ALIS), including its current price, market performance, key figures like market cap and P/E ratio, and shareholder information. It also presents technical analysis indicators and lists related instruments and popular market indices.

Materialise NV (MTLSN) Q1 2024 Earnings Report - Results, Call & Slides

Materialise NV (MTLSN) reported its Q1 2024 earnings, significantly beating the consensus EPS forecast with an actual EPS of $1.20 against an expected -$0.10. However, the company missed revenue expectations, reporting $1.21B against an anticipated $1.25B, marking a 2.30% year-over-year decline. The earnings call …

Palisade Bio, Inc. Revenue Breakdown – NASDAQ:PALI

Materialise NV (MTLS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

The article provides a detailed revenue breakdown for Materialise NV (MTLS) by business segment and geographical region. As of April 6, FY2024, the company's revenue streams are primarily from Manufacturing (39.93%), Medical devices and services (30.96%), and Software revenue (medical) (29.11%). Geographically, Europe accounts …

Zentalis Pharmaceuticals Inc (ZNTL) Institutional Confidence

Zentalis Pharmaceuticals Inc (ZNTL) has a strong institutional shareholding score of 10.00, ranking 1st in the Biotechnology & Medical Research industry. Institutional ownership stands at 90.22%, a 37.20% increase quarter-over-quarter. James Simons is the largest institutional shareholder, holding 2.73% of outstanding shares.

American Exceptionalism Acquisition Ord Shs Class A (AEXA) Institutional Confidence

This article provides details on the institutional confidence in American Exceptionalism Acquisition Ord Shs Class A (AEXA). It lists major institutional shareholders including Goldman Sachs & Company, Inc., Empyrean Capital Partners, LP, and D. E. Shaw & Co., L.P., along with their shareholdings and …

Materialise NV (MTLS) Valuation: PE, PB & Fair Value Analysis

The article provides a valuation analysis of Materialise NV (MTLS), noting its current valuation score of 7.83, ranking 313 out of 485 in the Software & IT Services industry. It highlights the company's P/E ratio of 44.35, comparing it to previous highs and lows. …

Borealis Foods Inc. Revenue Breakdown – NASDAQ:BRLS

Zentalis Pharmaceuticals Inc (ZNTL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a revenue breakdown for Zentalis Pharmaceuticals Inc (ZNTL), noting that relevant data regarding business segments, regional revenue, and profit contribution has not yet been disclosed by the company. It briefly presents the company's stock price, market cap, and P/E TTM. The …

Personalis (PSNL) Agrees To Tempus AI Deal As Shareholder Fairness Review Begins

Personalis (PSNL) has agreed to be acquired by Tempus AI. Following this announcement, Monteverde & Associates initiated an investigation into the fairness of the transaction terms for Personalis shareholders. The stock has seen significant short-term gains, but a mixed longer-term performance, making the acquisition …

Tempus to acquire Personalis in $1.5 billion deal to expand MRD capabilities

Tempus AI is set to acquire molecular diagnostics company Personalis for approximately $1.5 billion, enhancing Tempus's capabilities in molecular residual disease (MRD) testing and cancer monitoring. This acquisition follows a 2023 partnership and aims to integrate Personalis's MRD technology with Tempus's AI precision oncology …

PALI|Palisade Bio Inc|Price:1.950|Chg%:-0.070

Palisade Bio Inc (PALI) currently trades at $1.950, reflecting a 3.47% daily decrease. Despite recent stock performance, the company exhibits strong fundamentals, including high growth potential and a "Buy" rating from analysts with a target price of $10.40. Palisade Bio is a clinical-stage biopharmaceutical …

AEXA|American Exceptionalism Acquisition Ord Shs Class A|Price:11.540|Chg%:-0.010

This article provides a comprehensive overview of American Exceptionalism Acquisition Ord Shs Class A (AEXA), detailing its current stock price, key financial figures, and recent performance. It includes technical indicators and moving averages, offering insights into potential market trends. The report also lists major …